Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan plus fludarabine versus busulfan plus cyclophosphamide before allogeneic stem cell transplantation for AML in remission
2007-005803-16Phase 3Completed
- Sponsor
- GITMO (GRUPPO ITALIANO DI MIDOLLLO OSSEO)
- Start
- Jul 2008
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of busulfan, fludarabine, cyclophosphamide in acute myeloid leukemia (AML), sponsored by GITMO (GRUPPO ITALIANO DI MIDOLLLO OSSEO). Started Jul 2008; status: completed.
02
Drugs
busulfanfludarabinecyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-005803-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005803-16.